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The usefulness of anti-Müllerian hormone (AMH) for the quantitative evaluation of ovarian reserve has been
established. Therefore, serum AMH has been recently applied to the assessment of ovarian reserve outside infertility
treatment. We conducted a computer-based search, using keywords, through the PubMed database from inception
until May 2014 and summarized available studies evaluating ovarian damage caused by gynecologic diseases, such
as endometriosis and ovarian tumor, as well as surgical interventions, such as cystectomy and uterine artery
embolization (UAE), to discuss the usefulness of serum AMH. Most of the studies demonstrated a decline of serum
AMH levels after cystectomy for endometriomas. It is not conclusive whether electrocoagulation or suturing is
preferable. The effects of other gynecologic diseases and interventions, such as hysterectomy and UAE, on ovarian
reserve are controversial. Serum AMH levels should be considered in determining the indication and selection of
operative methods for benign gynecologic conditions.
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Benign gynecologic diseases are often implicated in
fertility problems, and therefore, fertility-preserving in-
terventions are required for such conditions. However,
surgical interventions involving the uterus and ovaries
have been demonstrated to possibly affect ovarian func-
tion, as these interventions might decrease ovarian tissue
levels and blood supply to ovaries [1-3].
The potential ovarian function at a given point in time
is now defined as the “ovarian reserve,” which reflects
the quality and quantity of follicles in the ovaries [4].
Therefore, interventions for gynecologic conditions aim-
ing to preserve fertility as well as benign gynecologic
diseases themselves must be assessed from the point of
view of ovarian reserve.* Correspondence: akiwase@med.nagoya-u.ac.jp
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unless otherwise stated.Follicle-stimulating hormone (FSH), a widely used
marker, was found to be insufficient for predicting ovar-
ian reserve after in vitro fertilization (IVF) [5]. Among
newly developed ovarian reserve tests, the serum level of
anti-Müllerian hormone (AMH) has been recognized as
an improved and informative marker [6,7]. AMH is pro-
duced by granulosa cells from preantral and small antral
follicles, and therefore, AMH levels indirectly represent
the total number of follicles, as estimated by the number
of early-growing-stage follicles [8,9]. AMH is reported to
be a better marker than FSH and inhibin B, and it dis-
plays similar performance as the antral follicle count in
predicting ovarian response [10]. One of the advantages
of serum AMH is its lower inter-cycle variability, distin-
guishing this variable from other markers including FSH
and inhibin B [11], although serum AMH levels are
reported to vary slightly during the menstrual cycle [12].
Therefore, many researchers have begun using serum
AMH levels to evaluate ovarian damage caused by surgical
interventions, such as ovarian cystectomy and uterine
artery embolization (UAE). Moreover, serum AMH levelshis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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analyzed to assess the value of AMH in predicting repro-
ductive lifespan [13].
In the current review, we mainly focused on the assess-
ment of ovarian reserve after gynecologic interventions.
We also included an assessment of the influence of gyne-
cologic diseases, such as endometriosis and endometrio-
mas, on ovarian reserve to discuss what mechanisms are
associated with the disturbance of ovarian reserve. Other
ovarian toxic interventions, such as chemotherapy and
radiotherapy, were not included in the current review to
maintain a focus on primary gynecologic conditions.
Methods
Sources
Articles were identified through a PubMed database search
covering the period from database’s inception through May
2014. We conducted a computer-based search of all
articles published in English using the keywords “AMH/
anti-Müllerian hormone and ovarian reserve” and
[“endometrioma,” “endometriosis,” “ovarian tumor,” “ovar-
ian cystectomy,” “uterine artery embolization/UAE,” “sal-
pingectomy,” or “hysterectomy”].
Study selection
We examined the 77 published studies identified using
the aforementioned keywords. For inclusion, articles
needed to describe the evaluation of ovarian reserve
using serum AMH levels in relation to benign gyneco-
logic conditions and/or interventions for such con-
ditions. Abstracts and review articles were excluded.
Articles evaluating ovarian reserve using other markers,
such as inhibin B and the antral follicle count, were not
included. Finally, 40 articles were chosen (22 for endo-
metriomas/endometriosis, 6 for other ovarian tumors/
cysts, and 12 for other interventions). In the current
review, we adopted the unit used in the original studies
to display AMH levels. Values presented in pmol/L can
be converted to ng/mL by dividing them by 7.14.
Results
Ovarian tumor, surgery, and intervention
Surgical interventions involving the uterine adnexa can
possibly cause damage to ovarian function because of
the loss of the ovarian cortex and/or detrimental effects
on blood supply to the ovaries [14]. Surgical procedures
include cystectomy for endometriomas and other benign
ovarian tumors, salpingectomy for hydrosalpinx, and
UAE for uterine leiomyoma, all of which are often per-
formed as part of infertility treatments. Therefore, de-
clines of ovarian reserve after these interventions must
be avoided as much as possible. Assessments of their
influence on ovarian reserve using serum AMH levels
may be helpful for improving these surgical interventions.On the contrary, ovarian cysts/tumors themselves might
affect ovarian reserve. Several published reports have in-
vestigated this point.
Endometrioma, endometriosis and ovarian reserve
The ovarian cortex surrounding endometriomas has
been revealed to possibly cause a reduction in the vol-
ume of healthy tissue, a lower follicular density, and a
loss of cortex-specific stroma [15-17]. These results sug-
gest that endometriomas might result in diminished
ovarian reserve. Lemos et al. first reported that infertile
patients with minimal/mild endometriosis, categorized
as revised American Society for Reproductive Medicine
(rASRM) classification stage I/II [18], have decreased
serum AMH levels compared to those in a control group
who had tubal obstruction without endometriosis (1.26 ±
0.7 ng/mL in the study group [median age, 29.5 years] vs.
2.02 ± 0.72 ng/mL in the control group [median age,
30.5 years], mean ± SD; P = 0.004) [19]. It is not likely that
the patients recruited in this study had endometriomas
because all patients had rASRM stage I/II endometriosis.
Concerning endometriomas, Kim et al. demonstrated that
patients with stage IV endometriosis with endometriomas
displayed significantly lower AMH levels than age- and
BMI-matched controls (2.1 ± 0.3 ng/mL vs. 3.1 ± 0.4 ng/mL,
mean ± SEM; P = 0.02) [20]. Similarly, it has been reported
that AMH levels are lower in patients with stage III/IV
endometriosis without prior ovarian surgery than in con-
trols (0.97 ± 0.59 ng/mL in the study group [mean age,
33.6 ± 1.9 years] vs. 1.72 ± 0.63 ng/mL in the control
group [mean age, 32.6 ± 2.0 years], mean ± SD; P = 0.001)
[21]. Uncu et al. also reported lower AMH levels in pa-
tients with endometrioma than in age-matched controls
(endometrioma vs. controls: 2.81 ± 2.15 ng/mL vs. 4.20 ±
2.26 ng/mL, mean ± SD; P = 0.002) [22]. In this study, the
unilateral endometrioma group exhibited lower AMH
levels than the bilateral endometrioma group. However, a
cross-sectional study including 313 women with a diagno-
sis of endometriosis and 413 women without endome-
triosis (control) identified no difference in serum AMH
levels related to the type of endometriosis excluding
women who had a past history of surgery for endometrio-
mas (4.1 ± 3.4 ng/mL for the control group, 4.5 ± 3.6 ng/
mL for the superficial peritoneal lesion group, 3.8 ±
2.9 ng/mL for the endometrioma group, 3.4 ± 3.0 ng/mL
for the deep infiltrating endometriosis group, mean ± SD;
P = 0.06) [23].
Surgery for endometrioma
Unlike the controversy regarding the influence of an
endometrioma itself on ovarian reserve, it appears con-
clusive that cystectomy for endometriomas diminishes
ovarian reserve. Chang et al. and Iwase et al. first repor-
ted that cystectomy for endometriomas leads to a greater
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benign ovarian tumors [24,25]. Subsequently, several simi-
lar studies have been published. Among these, only 1
study, in which preoperative serum AMH levels were
lower for patients’ ages than those in the other studies,
demonstrated that cystectomy for endometriomas did not
cause significant changes in serum AMH levels [26,27].
These studies have already been reviewed and meta-
analyzed, which led to the conclusion that cystectomy for
endometriomas may cause a decline of ovarian reserve
[28,29]. In addition to the studies comparing preoperative
and postoperative AMH levels, a cross-sectional study
also demonstrated that AMH levels were significantly
lower in women who previously underwent endometrio-
ma surgery, irrespective of whether endometriomas were
present at the time of the study (P < 0.05) [23].
Measurements of serum AMH levels make the quantita-
tive evaluation of the effects of surgery on ovarian reserve
possible. Consequently, several issues have emerged regar-
ding surgery for endometrioma and ovarian reserve. The
first issue is the incidence of post-surgical decreases in
ovarian reserve. Laparoscopic cystectomy for bilateral
endometriomas has been reported to possibly cause a
greater decline of serum AMH levels than unilateral cyst-
ectomy [24,25]. Hirokawa et al. reported that the serum
AMH levels 1 month after surgery compared with the
preoperative levels were 24.7 ± 32.5 and 62.8 ± 29.6%
lower for patients with unilateral and bilateral tumors,
respectively (P < 0.001) [30]. They also found that severe
endometriosis with higher rASRM scores tends to cause
greater declines of serum AMH levels after surgery.
Kitajima et al. reported that the decline of serum AMH
levels within 3 months after surgery was significantly
greater in women with an excised cyst wall that con-
tained normal ovarian tissue than in women without
healthy ovarian tissue in the excised cyst wall (42.0 ±
32.9% vs. 8.9 ± 13.4%; P = 0.01) [31]. In a 1-year follow up
study, the immediate postsurgical decline of serum
AMH levels was revealed to be possibly related to the
reduction of cortex volume from the excision, and
the medium/long-term decrease was believed to be
caused by other factors, including reduced blood supply to
the ovaries. [32]. Recently, a study of 193 patients who
underwent laparoscopic cystectomy for endometrioma
demonstrated that postoperative AMH levels significantly
decreased after surgery irrespective of age (≤38 years,
P < 0.001; >38 years, P < 0.001), cyst size (>3 cm, P =
0.018; ≤3 cm, P = 0.022), and laterality (unilateral, P < 0.001;
bilateral, P < 0.001) [33].
Another interesting issue is how various surgical
methods affect postoperative AMH levels. Cauterization
and vaporization of the cyst wall might have an advan-
tage in sparing ovarian reserve. The 3-step technique,
consisting of irrigation in the first laparoscopy, followedby gonadotropin-releasing hormone agonists and vapo-
rization in the second laparoscopy, resulted in a lower
postsurgical decline of AMH levels than endometrioma
stripping (3.9 ± 0.4 and 2.9 ± 0.2 ng/mL with stripping
vs. 4.5 ± 0.4 and 3.99 ± 0.6 ng/mL with the 3-step tech-
nique, mean ± SEM at baseline and 6 months after surgery;
P = 0.026 in the stripping group) [34]. Bipolar electro-
coagulation might damage the cortex of ovaries. Ferrero
et al. performed a randomized controlled trial (RCT) to
compare serum AMH levels following hemostasis by bipo-
lar coagulation versus suturing after laparoscopic cystec-
tomy for bilateral endometriomas [35]. They found no
significant difference in the mean percentage decrease of
AMH levels in the 2 groups after 3, 6, and 12 months of
follow-up. Another RCT was performed to compare
hemostatic matrix with bipolar electrocoagulation after
laparoscopic cystectomy for unilateral endometrioma [36].
Serum AMH levels in the bipolar coagulation group were
significantly lower at 1 month after surgery and similar at
3 months after surgery compared to those in the hemo-
static matrix group (hemostatic matrix vs. bipolar coagula-
tion: 3.73 ± 1.50 ng/mL vs. 3.66 ± 1.20 ng/mL preoperative,
2.72 ± 1.49 ng/mL vs. 1.64 ± 0.93 ng/mL in the 1st month,
and 3.07 ± 1.43 ng/mL vs. 2.84 ± 1.12 ng/mL in the 3rd
month, mean ± SD; P = 0.001 and P = 0.467 in the 1st and
3rd months, respectively). Zaitoun et al. prospectively com-
pared laparoscopic cystectomy with bipolar coagulation
and laparotomic cystectomy with sutures. Only the laparo-
scopic cystectomy group displayed a significant decrease
of AMH levels (4.5 ± 0.8, 2.4 ± 0.5, 2.7 ± 0.5, and 2.5 ±
0.4 ng/mL in the laparoscopic group vs. 4.6 ± 0.9, 4.5 ± 0.9,
4.4 ± 0.9, and 4.5 ± 0.9 ng/mL in the laparotomy group
preoperatively and 6, 12, and 18 months after surgery,
respectively; mean ± SD, P = 0.8, P < 0.005, P < 0.005, and
P < 0.005 preoperatively and 6, 12, and 18 months after
surgery, respectively) [37].
Another issue is the recovery of serum AMH levels
after surgery for endometriomas. AMH is produced by
primary, preantral, and small antral follicles but not pri-
mordial follicles [9]. If rearrangements of follicle cohorts
from a healthy primordial follicle pool occur, then serum
AMH levels that decreased as a result of surgery could
recover. Two early studies indicated that serum AMH
levels might be restored to some extent by 1 week,
1 month, and 3 months after cystectomy for endome-
triomas [24,38]. In the aforementioned RCT, AMH levels,
especially in the bipolar coagulation group, tended to re-
cover at 3 months after surgery compared with 1 month
after surgery [36]. On the contrary, several studies demon-
strated that serum AMH levels gradually decreased or
remained depressed [22,35,39,40]. Celik et al. assessed
serum AMH levels preoperatively and at 6 weeks and
6 months after surgery and reported that AMH levels
gradually decreased patients with bilateral tumors or those
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that serum AMH levels could be higher or lower
12 months after surgery compared to those 1 month after
surgery [32].
Other benign ovarian cysts
The effects of cystectomy for benign ovarian tumors on
AMH levels have been assessed in a few studies. Iwase
et al. reported that laparoscopic cystectomy for non-
endometriomas (15 cases of unilateral tumors and 5
cases of bilateral tumors) caused a lesser, but significant,
decline of AMH levels (3.92 and 3.29 ng/mL before and
after cystectomy, respectively, median; P = 0.044) [25].
Similarly, another study reported that serum AMH levels
were lower 1 week after laparoscopic cystectomy for non-
endometriotic cysts (69.2% of the preoperative AMH
levels; P < 0.05) [24]. Jang et al. recently reconfirmed the
results from Iwase and Chang [41]. Thus far, only 1 pro-
spective randomized study has compared serum AMH
levels after cystectomy for unilateral non-endometriotic
cysts using laparoscopy and laparotomy [42]. Significant
differences were found in AMH levels between the lapar-
oscopy and laparotomy groups at 1, 3, and 6 cycles after
cystectomy (4.2, 3.2, 2.6, and 2.4 ng/mL in the laparoscopy
group vs. 4.6, 3.7, 3.5, and 3.6 ng/mL in the laparotomy
group before and 1, 3, and 6 cycles after cystectomy,
respectively, mean; P = 0.180, P = 0.004, P < 0.001, and
P < 0.001, respectively). No significant difference was
observed in preoperative serum AMH levels between
the mature cystic teratoma group and age- and BMI-
matched controls (4.0 ± 0.5 ng/mL vs. 4.0 ± 0.5 ng/mL,
mean ± SEM; not significant) [20]. The decline rates
of serum AMH levels after cystectomy for benign
ovarian tumors have been reported to be lower than
those observed after cystectomy for endometriomas.
Chang et al. reported that the decline in serum AMH
levels at 1 week after laparoscopic cystectomy was
smaller for non-endometriotic cysts than for endome-
trioma (69.2% vs. 33.9% of preoperative AMH levels;
P = 0.028) [24]. A similar tendency was reported by
Iwase et al. (the extent of decline compared to preopera-
tive levels: 16.1% in the benign ovarian tumor group vs.
24.9% in the endometrioma group) [25]. On the contrary,
it was recently reported that the rate of AMH decline at
3 months after laparoscopic cystectomy did not differ
between the endometrioma group and the other benign
ovarian cyst group (36.64 ± 29.20% vs. 30.58 ± 29.66% of
the preoperative level; P = 0.36) [43].
Other interventions that affect ovarian reserve
Hydrosalpinx can reduce the likelihood of pregnancy
after IVF. Therefore, salpingectomy of diseased fallopian
tubes before IVF should be considered [44]. Salpingec-
tomy might result in decreased blood supply to theovaries. However, the ovarian response after salpingec-
tomy has been inconsistent [45,46]. In a cross-sectional
study, no significant differences were found in serum
AMH levels among patients with varying tubal status,
including 26, 34, 23, and 51 patients who underwent
bilateral salpingectomy, unilateral salpingectomy, bilateral
interruption in the proximal oviducts, and bilateral
oviduct obstruction, respectively [47]. On the contrary,
Grynnerup et al. reported that AMH levels were signifi-
cantly lower in the salpingectomy group than in the non-
salpingectomy group (16.1 pmol/L [median age, 34 years]
vs. 23.4 pmol/L [median age, 33 years], median; P = 0.04)
[48]. Sequential assessments of serum AMH levels did not
reveal statistically significant differences before and after
laparoscopic coagulation and dissection of the prox-
imal tubes (1.548 ng/mL preoperatively vs. 1.481 ng/mL
3 months after surgery, median; P = 0.079) [49]. Similarly,
research illustrated that serum AMH levels were not
affected by tubal ligation (1.43 ng/mL preoperatively
vs. 1.30 ng/mL 12 months after surgery, median;
P = 0.23) [50].
Hysterectomy, even if the ovaries are preserved, has
been reported to possibly cause adverse effects on ovarian
function, which might shorten the time to menopause
[51,52]. Atabekoglu et al. reported that serum AMH levels
tended to decline more at 4 months after hysterectomy
compared to those in controls who did not undergo hys-
terectomy (1.46 ± 2.02 to 0.62 ± 0.9 ng/mL in the hysterec-
tomy group vs. 1.53 ± 1.82 to 1.26 ± 1.78 ng/mL in the
controls, mean ± SD, P = 0.73 and P = 0.262 before and
after surgery, respectively) [53]. The authors concluded
that the decrease in ovarian reserve after hysterectomy is
possibly caused by hypoxia as a result of the interruption
of the uterine arteries. However, Lee at al. revealed that
hysterectomy did not affect ovarian artery blood flow
or serum AMH levels (1.80 ± 1.81 ng/mL preopera-
tively in women aged 44.2 ± 3.5 years vs. 1.52 ± 1.72 ng/ml
at 3 months after hysterectomy, mean ± SD; P = 0.805)
[54]. Wang et al. demonstrated that serum AMH levels
significantly declined 3 months following hysterectomy,
whereas those 3 months after myomectomy were similar
to the preoperative levels (1.08 ± 0.77 ng/mL vs. 0.81 ±
0.55 ng/mL in the hysterectomy group; P < 0.01; 1.54 ±
0.95 ng/mL vs. 1.50 ± 0.58 ng/mL in the myomectomy
group; P = 0.07; mean ± SD preoperatively and 3 months
after surgery) [55]. In another point of view, prophylac-
tic salpingectomy with total laparoscopic hysterectomy
(TLH) did not cause a significant decrease of AMH
levels compared to those observed after standard TLH
with adnexal observation (−0.06 ± 0.1 ng/mL vs. −0.08 ±
0.1 ng/mL ΔAMH for TLH with vs. without salpingec-
tomy, mean ± SD; P = 0.35) [56]. This result was recon-
firmed in an RCT (2.26 ± 2.72 ng/mL and 1.86 ± 1.99 ng/
mL in the bilateral salpingectomy with hysterectomy group
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gectomy group, mean ± SD at baseline and 3 months after
surgery; P = 0.99 and P = 0.97, respectively) [57].
UAE has been introduced as an effective treatment for
severe hemorrhage related to pregnancy and has been
proposed as a replacement for hysterectomy for some
patients with uterine leiomyoma [58,59]. However, the
possible decline of ovarian reserve after UAE remains
controversial. Hehenkamp et al. measured serum AMH
levels at baseline and at several time points during
follow-up after UAE and hysterectomy and found that
AMH levels remained significantly lower during the
follow-up period in the UAE group but not in the hys-
terectomy group [60]. Similar results were reported by
Arthur et al., who compared UAE and laparoscopic myo-
mectomy (2.17 ng/mL after laparoscopic myomectomy vs.
0.78 ng/mL after UAE, median; P = 0.01) [61]. On the con-
trary, the combination of UAE and local methotrexate for
interstitial pregnancies did not appear to reduce ovarian
reserve based on AMH levels, although only 3 cases were
analyzed [62]. Figure 1 presents the gynecologic diseases
and interventions in which assessments of ovarian reserve
using AMH have been reported.
Discussion
Main findings and limitations
As we reviewed manuscripts for this article, the following
results were demonstrated: 1) the influence of endome-
triosis/endometrioma itself on ovarian reserve remains
controversial, 2) cystectomy for endometriomas tends to
reduce AMH levels more severely than that for other
types of benign ovarian tumors, especially for bilateral or
severe disease, 3) cystectomy and bipolar coagulation in
endometrioma surgery could be the factors that decreaseFigure 1 Possible factors that affect ovarian reserve in patients with bovarian reserve. However, it is not conclusive which surgi-
cal method is preferable from the point of view of ovarian
reserve, 4) although hysterectomy, salpingectomy, and
UAE might affect ovarian reserve, there is insufficient
evidence to draw a conclusion.
One of the limitations of our study is the high hetero-
geneity of the included articles. Serum AMH levels were
primarily affected by the recruited patients’ ages, which
differed among the studies. Another limitation is that
the significance of the decrease in serum AMH levels
after the interventions is not conclusive, as the changes
were possibly encompassed by the wide normal range
for serum AMH [13]. However, this review involved the
systematic collection of articles to assess ovarian reserve
in relation to gynecologic diseases and interventions and
the narrative evaluation of the articles.
Interpretation and future perspective
The clinical potential of measuring serum AMH levels
has been evaluated in a wide range of healthcare issues
outside assisted reproductive technology, including as-
sessments for ovarian damage caused by chemotherapy,
radiation, surgery, and possible predictors for meno-
pause [63,64].
In the current review, we focused on the usefulness of
AMH for evaluating ovarian damage caused by gyneco-
logic interventions, such as surgery and embolization. Re-
garding endometriomas, 2 randomized studies illustrated
that stripping was superior to vaporization or coagulation
of the cyst wall in terms of the rates of spontaneous preg-
nancy and disease recurrence [65-67]. However, vapori-
zation or coagulation has been demonstrated to be more
favorable in terms of ovarian reserve [14]. Therefore, the
increasingly widespread use of AMH measurements hasenign gynecologic conditions. UAE, uterine artery embolization.
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cal methods for treating endometriomas. As we previously
mentioned, several studies revealed that cystectomy
for endometriomas causes a decrease of ovarian re-
serve, especially in cases of bilateral disease. Disturb-
ance of the blood supply has been considered one of
the reasons to affect ovarian reserve in endometrioma
cystectomy. A small number of studies revealed that
suturing or using hemostatic materials without bipolar
electrocoagulation might be preferable in the preserving
ovarian reserve. Further studies, including those of
the rates of pregnancy and recurrence after surgery, are
needed to evaluate the true usability of serum AMH levels
after endometrioma surgery.
In addition to endometrioma surgery, surgical inter-
ventions that might cause ovarian damage should be
evaluated in terms of ovarian reserve. It is controversial
whether cystectomy for benign ovarian tumors excluding
endometriomas negatively affects ovarian reserve. How-
ever, the influence should be less than that of cystectomy
for endometriomas. UAE is performed for leiomyoma
and postpartum hemorrhage. Possible damage to the
ovaries is a problem if these patients desire pregnancy in
the future. Declines of ovarian reserve possibly caused
by salpingectomy, which is occasionally performed for
ectopic pregnancy and hydrosalpinx, could also be an
issue. Ovarian function is important from the point of
view of women’s healthcare. Therefore, considering ovar-
ian function after hysterectomy, the assessment for ovar-
ian reserve using AMH has a role. The studies thus far
have not demonstrated a huge influence, although the
impact of such interventions on ovarian reserve by is not
conclusive.
Conclusions
In conclusion, serum AMH is helpful for counseling
patients who desire future fertility but have benign gyne-
cologic conditions that may require surgical interventions.
Serum AMH levels may be preferred in determining the
indication and selection of operative methods for benign
gynecologic conditions, especially endometriomas. How-
ever, there is little available information regarding the
correlation between the possibility of live birth and serum
AMH levels before and after interventions. Further studies
are required to investigate whether and how serum AMH
levels in patients with benign gynecologic conditions are
relevant to prospective live birth.
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